Agomab Therapeutics (AGMB) Receivables (2024 - 2025)
Agomab Therapeutics (AGMB) posted quarterly Receivables of $7.1 million for Q4 2025, up 113.1% year-over-year from $3.3 million in Q4 2024, and up 113.1% quarter-over-quarter from $3.3 million in Q4 2024.
Agomab Therapeutics (AGMB) Receivables (2024 - 2025) Analysis & Trends
Agomab Therapeutics' Receivables history runs 2 years deep, the most recent figure standing at $7.1 million for Q4 2025.
- In Q4 2025, Receivables rose 113.1% year-over-year to $7.1 million; the TTM figure through Dec 2025 stood at $7.1 million (up 113.1% YoY), while the FY2025 annual figure was $7.1 million, up 110.4% from the prior year.
- Receivables for Q4 2025 stood at $7.1 million, up from $3.3 million in the prior quarter.
- The five-year high for Receivables was $7.1 million in Q4 2025, with the low at $3.3 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.90 Bn | 131.05 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 86.10 Bn | 78.11 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 65.56 Bn | 60.37 Bn | 1.37 Bn | 1.93 Bn |
| 4 | Moderna | 55.82 Bn | 50.68 Bn | 52.00 Mn | 160.00 Mn |
| 5 | BeOne Medicines | 42.14 Bn | 37.04 Bn | 1.53 Bn | 1.06 Bn |
| 6 | Alnylam Pharmaceuticals | 31.67 Bn | 28.36 Bn | 992.69 Mn | 912.74 Mn |
| 7 | BioNTech SE | 27.74 Bn | 9.35 Bn | 668.28 Mn | 1.09 Bn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | 215.33 Mn |
| 9 | Royalty Pharma | 27.38 Bn | 26.54 Bn | - | - |
| 10 | Agomab Therapeutics | 7.32 Mn | -250.26 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 7.14 Mn |
| Dec 31, 2024 | 3.35 Mn |